Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2020
Event: Entry into a Material Definitive Agreement to acquire Purnovate, LLC, a drug development company focused on non-opioid pain reduction and adenosine analogs. The acquisition is expected to close in January 2021.
Key Financial Metrics and Transaction Terms
Acquisition Consideration:
- Cash Consideration: $350,000 payable at closing.
- Stock Consideration: 700,000 shares of Adial restricted common stock (exempt from registration).
- Royalties: 3.0% of Net Sales.
- Milestone Payments: Up to $21,500,000 contingent on development and commercialization achievements (e.g., $10,000,000 for first U.S. commercial sale).
- Adial loaned Purnovate $350,000 via a 3.5% promissory note due December 7, 2021.
- The note is convertible into Purnovate membership interests at $1.50 per unit if the acquisition is terminated.
- Net Loss (10 months ended Oct 31, 2020): Approximately $300,000.
- Accumulated Deficit: Approximately $300,000.
- Working Capital: Approximately $53,000.
- The issuance of stock consideration is expected to dilute existing Adial stockholders by approximately 4.6%.
Material Changes and Strategic Rationale
Strategic Benefits:
- Pipeline Diversification: Expands Adial's addiction-related pipeline with non-opioid pain management candidates and potential cocaine addiction treatments.
- Technology Acquisition: Gains access to Purnovate's purification and solubilizing platform technologies and chemistry expertise, which Adial currently lacks internally.
- Operational Synergy: Simplifies integration as Adial currently subleases its corporate offices from Purnovate.
- Adial CEO William B. Stilley and Board Member James W. Newman are members of Purnovate.
- A Special Committee of independent directors was formed to review and negotiate the terms.
Outlook, Risks, and Contingencies
Conditions to Closing:
- Receipt of a fairness opinion from Adial's financial advisor.
- Execution of lock-up agreements (1 year for most members; 2 years for CEO Dr. Thompson and Adial CEO Mr. Stilley).
- Dr. Thompson must enter a 2-year employment agreement with Adial.
- Development Risk: Purnovate's lead product has not yet entered clinical trials; safety and efficacy are unproven.
- Financial Risk: Purnovate has a limited operating history and expects continued negative cash flows. Adial may need to raise additional capital, potentially causing further dilution.
- Market Risk: Adial stock price volatility could alter the value of the stock consideration prior to closing.
- Integration Risk: Challenges in assimilating technology and retaining personnel.
Investor Verification Checklist
- Verify the status of the fairness opinion required as a condition to closing.
- Review the full text of the Equity Purchase Agreement (Exhibit 10.1) for specific indemnification and escrow terms.
- Monitor Adial's capital raising activities to fund the acquisition and Purnovate's ongoing R&D expenses.
- Assess the timeline for Purnovate's first human dosing to trigger the initial $300,000 milestone payment.
- Confirm the extent of related party interests held by Adial's CEO and Board in the acquired entity.